APHA:NSD-Aphria Inc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NSD

Last Closing Price

USD 4.31

Change

+0.08 (+1.89)%

Market Cap

USD 1.21B

Volume

2.08M

Average Target Price

USD 8.41 (+95.11%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-28 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

+0.22 (+1.53%)

USD7.45B 26.81 7.09
MNTA Momenta Pharmaceuticals, Inc

+0.06 (+0.11%)

USD6.23B N/A N/A
PCRX Pacira BioSciences, Inc

+0.46 (+0.78%)

USD2.52B 870.20 73.37
CRON Cronos Group Inc

-0.12 (-2.36%)

USD1.77B 2.44 N/A
IRWD Ironwood Pharmaceuticals, Inc

+0.08 (+0.85%)

USD1.51B 15.26 12.72
ATNX Athenex, Inc

-0.12 (-0.97%)

USD1.14B N/A N/A
SUPN Supernus Pharmaceuticals, Inc

+0.47 (+2.31%)

USD1.07B 9.18 5.84
PETQ PetIQ, Inc

+1.12 (+3.51%)

USD0.91B 134.36 111.60
AMPH Amphastar Pharmaceuticals, Inc

+0.48 (+2.66%)

USD0.86B 224.88 27.46
ENDP Endo International plc

-0.08 (-2.44%)

USD0.75B N/A 8.10

ETFs Containing APHA

Symbol Name Weight Mer Price(Change) Market Cap
MJ ETFMG Alternative Harvest.. 0.00 % 0.75 %

-0.03 (-0.29%)

USD0.56B
CNBS Amplify Seymour Cannabis .. 0.00 % 0.75 %

-0.01 (-0.09%)

N/A
THCX The Cannabis ETF 0.00 % 0.70 %

-0.01 (-0.12%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -17.43% 68% D+ 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.43% 68% D+ 39% F
Trailing 12 Months  
Capital Gain -16.96% 62% D- 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.96% 62% D- 35% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -18.90% N/A N/A 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.90% N/A N/A 10% F
Risk Return Profile  
Volatility (Standard Deviation) 24.16% N/A N/A 61% D-
Risk Adjusted Return -78.25% N/A N/A 7% F
Market Capitalization 1.21B 92% A- 72% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 57.50 23% F 19% F
Price/Book Ratio 0.89 87% B+ 76% C
Price / Cash Flow Ratio -9.07 82% B- 80% B-
EV/EBITDA 392.34 4% F 2% F
Management Effectiveness  
Return on Equity -4.74% 80% B- 47% F
Return on Invested Capital -0.06% 77% C+ 46% F
Return on Assets 0.07% 79% C+ 47% F
Debt to Equity Ratio 22.09% 54% F 62% D-
Technical Ratios  
Short Ratio 8.12 41% F 18% F
Short Percent N/A N/A N/A N/A N/A
Beta 2.02 19% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector